NCT02844491

Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 28 (actual)
• Sponsor: Centre Hospitalier Universitaire de Besancon · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform. The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides. If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.

Conditions

• Hematological Malignancies B

Interventions

Type	Name	Description
OTHER	additional biological samples	blood and tissue samples

Timeline

• Start date: 2013-01-22
• Primary completion: 2014-09-19
• Completion: 2014-09-19
• First posted: 2016-07-26
• Last updated: 2021-02-02

Locations

1 site across 1 country: France